港股上市公司翰森制药（03692.HK）今日盘中大涨6.77%，引发市场广泛关注。截至收盘，该股报23.55港元，成交额达4.05亿港元。
翰森制药股价上涨主要受两方面因素推动。首先，公司2024年财报超出市场预期。交银国际指出，翰森制药2024年收入和净利润分别增长21.3%和33.4%，达到123亿元和43.7亿元。创新药收入95亿元，其中产品收入约80亿元，同比增长28.5%，对总收入贡献约65%。
其次，公司主打产品阿美乐（Ameile）销售前景看好。摩根士丹利报告称，阿美乐销售峰值指引从60亿元人民币上调至80亿元人民币，并设定2025年60亿元人民币销售目标。此外，管理层预计今年产品销售将实现双位数增长，其中创新药将实现25%增长。这些利好消息激发了投资者信心，推动翰森制药股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.